冠心病患者血清抗凝血酶原抗体的检测  

Clinical Significance of Antiprothormbin Antibody in CHD Patients

作　　者：林青[1] 彭维林[2] 李庶甘[1] 唐文吟[2] 张毅[1] 赵越真[2] 张荣盛[1] 苏东辉[3] 

机构地区：[1]厦门出入境检验检疫局国际旅行保键中心实验室,福建厦门361012 [2]福建泉州市儿童医院/妇幼保健院,福建泉州362000 [3]福建医科大学医学检验系,福州350003

出　　处：《现代检验医学杂志》2007年第6期13-16,共4页Journal of Modern Laboratory Medicine

摘　　要：目的检测冠心病(CHD)患者血清中抗凝血酶原抗体(aPT)的含量,以探求其与该病的临床相关性。方法应用间接ELISA法检测HCD患者血中的aPT(IgG及IgM型)及总抗磷脂抗体(aPL)(IgG及IgM型),同时计算其阳性率和优势比(OR,95%置信区间)。结果49例CHD病人IgG,IgM,IgG/IgM-aPL的阳性率分别为22.4%,14.3%和28.6%,而对照组分别为5%,5%和10%,说明aPL在CHD病人中有明显的升高(除了IgM外,P<0.05)。CHD病人的IgG,IgM,IgG/IgM-aPT的阳性率分别为12.2%,10.2%和18.4%,对照组为2.5%,2.5%和5%,虽aPT有高于对照组的趋势,但无统计学意义(均P>0.05)。尽管如此,在AMI病人中aPL和aPT均比OMI和AP病人高,aPT更为明显。结论aPT可能是AMI的危险因素之一。aPL和aPT在一些CHD病人血清中有较高的水平,检测这些患者血中的aPL及aPT,将有助于进一步完善抗磷脂抗体综合征(APS)的临床研究及这些疾病的预防、诊断及治疗。Objective To study the correlation between antiprothrombin antibody （aPT）and the possible mechanism of coronary heart disease（CHD）. Methods The levels of antiphospholipid antibody（aPLs） and the total aPT in serum including IgG and IgM were detected by indirect solid phase ELISA in the patients and healthy subjects. Results The positive rates of IgG,IgM,IgG/IgM-aPL in 49 patients with CHD were 22. 4%, 14.3% and 28.6% ,respectively,compared with 5%, 5 % andl0% of 40 controls. There were significant differences （P〈 0.05） except IgM ; those of IgG,IgM, IgG/ IgM-aPT in the patients were 12.2%,10.2% and 18.4%,compared with 2.5%,2.5%and 5% in the controls. Although the former were higher than the latter,there were no statistical differences. However,the positive rate of aPT in 13 patients with AMI were higher than those in OMI and AP. Conclusion APT may be a risk factor to AMI,propose that these antibodies should be further explored ,not only for clinical research about APS,but also for the prevention,diagnosis, and treatment of a series autoimmune-related diseases.

关 键 词：凝血酶原 磷脂 抗体 冠心病 

分 类 号：R541.4[医药卫生—心血管疾病] R446.62[医药卫生—内科学]